Login to Your Account

Financings NEWS

DUBLIN – Pharma Two B Ltd., a privately held specialty pharma firm, closed its third round of funding at $30 million in order to complete clinical development and registration of its lead program, P2B001, a combination therapy for Parkinson's disease, and to add additional products to its portfolio.

Arrakis Therapeutics Inc., a company seeking to develop a pipeline of RNA-targeted small molecules for neurology, oncology and rare genetic disorders, has completed a $38 million series A financing.

After several years incubating in the Centre for Probe Development and Commercialization at McMaster University in Hamilton, Ontario, Fusion Pharmaceuticals Inc. is hanging out its shingle.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: